Mevrometostat plus enzalutamide in metastatic castration-resistant

Will PF-06821497 (mevrometostat) with enzalutamide meet the primary endpoint of radiographic progression-free survival (rPFSOutcome measureProgression-Free Survival (PFS)rPFS is defined as the time from randomization to first objective evidence of radiographic progression by RECIST v1.1 or PCWG3 guidelines by blinded independent central review, or death, whichever occurs first.Primary outcome | Randomization up to approximately 3 yearsClinicalTrials.gov outcome) in NCT06629779?